Cansino Research Development vs Ebitda Analysis

688185 Stock

61.23 0.13 0.21%

Cansino Biologics financial indicator trend analysis is way more than just evaluating Cansino Biologics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cansino Biologics is a good investment. Please check the relationship between Cansino Biologics Research Development and its Ebitda accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cansino Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Research Development vs Ebitda

Research Development vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cansino Biologics Research Development account and Ebitda. At this time, the significance of the direction appears to have no relationship.

The correlation between Cansino Biologics' Research Development and Ebitda is 0.07. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Ebitda in the same time period over historical financial statements of Cansino Biologics, assuming nothing else is changed. The correlation between historical values of Cansino Biologics' Research Development and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Cansino Biologics are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Research Development i.e., Cansino Biologics' Research Development and Ebitda go up and down completely randomly.

Correlation Coefficient

0.07

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Research Development

Ebitda

Most indicators from Cansino Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cansino Biologics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cansino Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

The current year's Selling General Administrative is expected to grow to about 680.2 M, whereas Tax Provision is forecasted to decline to (12 M).

	2021	2022	2023	2024 (projected)
Interest Income	79.7M	65.9M	100.1M	105.1M
Net Interest Income	59.0M	24.1M	35.7M	27.1M

Interest Income Net Interest Income

Cansino Biologics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets
Total Assets		0.86	0.95	0.98	0.97	0.98	0.84	-0.07	0.77	0.92	0.92	0.84	0.79	0.6	0.76	0.84	0.96	0.75	0.95	0.91	-0.67	0.94	0.64	1.0	0.88	0.99
Other Current Liab	0.86		0.9	0.79	0.85	0.82	0.79	-0.37	0.59	0.66	0.91	0.78	0.94	0.88	0.92	0.89	0.9	0.95	0.8	0.8	-0.59	0.92	0.62	0.85	0.99	0.8
Total Current Liabilities	0.95	0.9		0.88	0.91	0.9	0.74	-0.03	0.76	0.77	0.95	0.74	0.79	0.66	0.82	0.81	0.99	0.79	0.95	0.91	-0.58	0.99	0.58	0.94	0.93	0.91
Total Stockholder Equity	0.98	0.79	0.88		0.94	0.98	0.85	-0.07	0.77	0.97	0.85	0.86	0.73	0.5	0.67	0.82	0.89	0.66	0.92	0.88	-0.69	0.85	0.61	0.99	0.8	0.99
Other Liab	0.97	0.85	0.91	0.94		0.99	0.86	-0.26	0.62	0.86	0.95	0.86	0.83	0.66	0.77	0.93	0.91	0.78	0.84	0.85	-0.68	0.93	0.75	0.98	0.85	0.93
Net Tangible Assets	0.98	0.82	0.9	0.98	0.99		0.86	-0.17	0.71	0.92	0.91	0.87	0.77	0.57	0.69	0.89	0.9	0.71	0.88	0.89	-0.69	0.89	0.68	0.99	0.82	0.96
Net Debt	0.84	0.79	0.74	0.85	0.86	0.86		-0.41	0.53	0.78	0.82	1.0	0.84	0.66	0.71	0.86	0.77	0.76	0.71	0.72	-0.78	0.75	0.85	0.86	0.78	0.81
Retained Earnings	-0.07	-0.37	-0.03	-0.07	-0.26	-0.17	-0.41		0.42	0.04	-0.3	-0.4	-0.6	-0.68	-0.44	-0.55	-0.03	-0.58	0.19	0.05	0.22	-0.14	-0.58	-0.12	-0.29	0.02
Accounts Payable	0.77	0.59	0.76	0.77	0.62	0.71	0.53	0.42		0.8	0.56	0.54	0.35	0.14	0.34	0.46	0.75	0.34	0.91	0.87	-0.43	0.66	0.14	0.74	0.61	0.83
Cash	0.92	0.66	0.77	0.97	0.86	0.92	0.78	0.04	0.8		0.7	0.78	0.58	0.33	0.5	0.71	0.78	0.51	0.87	0.84	-0.63	0.72	0.47	0.92	0.66	0.96
Non Current Assets Total	0.92	0.91	0.95	0.85	0.95	0.91	0.82	-0.3	0.56	0.7		0.82	0.9	0.79	0.89	0.91	0.95	0.88	0.82	0.82	-0.62	0.98	0.78	0.92	0.93	0.85
Non Currrent Assets Other	0.84	0.78	0.74	0.86	0.86	0.87	1.0	-0.4	0.54	0.78	0.82		0.83	0.65	0.7	0.85	0.76	0.75	0.71	0.73	-0.77	0.75	0.86	0.86	0.77	0.81
Other Assets	0.79	0.94	0.79	0.73	0.83	0.77	0.84	-0.6	0.35	0.58	0.9	0.83		0.96	0.95	0.91	0.79	0.99	0.65	0.65	-0.59	0.84	0.79	0.8	0.93	0.71
Long Term Debt	0.6	0.88	0.66	0.5	0.66	0.57	0.66	-0.68	0.14	0.33	0.79	0.65	0.96		0.95	0.8	0.66	0.98	0.46	0.47	-0.44	0.74	0.7	0.61	0.86	0.49
Net Receivables	0.76	0.92	0.82	0.67	0.77	0.69	0.71	-0.44	0.34	0.5	0.89	0.7	0.95	0.95		0.79	0.83	0.97	0.67	0.61	-0.51	0.87	0.7	0.76	0.95	0.68
Common Stock Shares Outstanding	0.84	0.89	0.81	0.82	0.93	0.89	0.86	-0.55	0.46	0.71	0.91	0.85	0.91	0.8	0.79		0.8	0.87	0.68	0.76	-0.64	0.85	0.76	0.86	0.85	0.78
Short Term Investments	0.96	0.9	0.99	0.89	0.91	0.9	0.77	-0.03	0.75	0.78	0.95	0.76	0.79	0.66	0.83	0.8		0.79	0.95	0.87	-0.65	0.98	0.6	0.94	0.93	0.92
Non Current Liabilities Total	0.75	0.95	0.79	0.66	0.78	0.71	0.76	-0.58	0.34	0.51	0.88	0.75	0.99	0.98	0.97	0.87	0.79		0.63	0.63	-0.54	0.84	0.72	0.75	0.94	0.66
Inventory	0.95	0.8	0.95	0.92	0.84	0.88	0.71	0.19	0.91	0.87	0.82	0.71	0.65	0.46	0.67	0.68	0.95	0.63		0.93	-0.57	0.89	0.44	0.93	0.84	0.96
Other Current Assets	0.91	0.8	0.91	0.88	0.85	0.89	0.72	0.05	0.87	0.84	0.82	0.73	0.65	0.47	0.61	0.76	0.87	0.63	0.93		-0.4	0.87	0.5	0.89	0.8	0.91
Other Stockholder Equity	-0.67	-0.59	-0.58	-0.69	-0.68	-0.69	-0.78	0.22	-0.43	-0.63	-0.62	-0.77	-0.59	-0.44	-0.51	-0.64	-0.65	-0.54	-0.57	-0.4		-0.58	-0.55	-0.69	-0.58	-0.66
Total Liab	0.94	0.92	0.99	0.85	0.93	0.89	0.75	-0.14	0.66	0.72	0.98	0.75	0.84	0.74	0.87	0.85	0.98	0.84	0.89	0.87	-0.58		0.65	0.92	0.95	0.88
Deferred Long Term Liab	0.64	0.62	0.58	0.61	0.75	0.68	0.85	-0.58	0.14	0.47	0.78	0.86	0.79	0.7	0.7	0.76	0.6	0.72	0.44	0.5	-0.55	0.65		0.67	0.64	0.55
Net Invested Capital	1.0	0.85	0.94	0.99	0.98	0.99	0.86	-0.12	0.74	0.92	0.92	0.86	0.8	0.61	0.76	0.86	0.94	0.75	0.93	0.89	-0.69	0.92	0.67		0.87	0.98
Short Long Term Debt	0.88	0.99	0.93	0.8	0.85	0.82	0.78	-0.29	0.61	0.66	0.93	0.77	0.93	0.86	0.95	0.85	0.93	0.94	0.84	0.8	-0.58	0.95	0.64	0.87		0.82
Total Current Assets	0.99	0.8	0.91	0.99	0.93	0.96	0.81	0.02	0.83	0.96	0.85	0.81	0.71	0.49	0.68	0.78	0.92	0.66	0.96	0.91	-0.66	0.88	0.55	0.98	0.82

Click cells to compare fundamentals

Cansino Biologics Account Relationship Matchups

Cansino Biologics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.8B	6.7B	11.9B	11.5B	9.3B	6.7B
Other Current Liab	57.7M	142.3M	544.4M	637.0M	732.5M	769.2M
Total Current Liabilities	116.4M	409.5M	2.9B	2.9B	2.6B	1.4B
Total Stockholder Equity	1.5B	6.1B	8.0B	6.7B	5.3B	4.5B
Other Liab	59.8M	174.0M	202.0M	222.4M	255.7M	134.3M
Net Tangible Assets	1.5B	6.0B	7.8B	6.5B	7.5B	4.2B
Retained Earnings	(368.1M)	(764.7M)	1.1B	42.7M	(1.6B)	(1.5B)
Accounts Payable	6.2M	60.6M	842.6M	253.1M	104.0M	200.3M
Cash	202.5M	4.4B	5.5B	3.4B	2.0B	2.5B
Non Current Assets Total	990.3M	1.3B	2.6B	3.7B	4.1B	2.2B
Other Assets	88.7M	151.1M	148.6M	398.7M	458.5M	481.5M
Long Term Debt	130M	90M	40M	878.0M	1.1B	1.1B
Net Receivables	15.4K	21.6M	157.9M	855.5M	636.9M	668.7M
Short Term Investments	552.3M	666.6M	2.3B	2.6B	2.1B	1.4B
Non Current Liabilities Total	189.7M	264.4M	451.4M	1.3B	1.4B	1.5B
Inventory	16.3M	170.5M	875.6M	677.8M	350.7M	330.2M
Other Current Assets	23.1M	114.1M	454.5M	245.0M	281.8M	181.3M
Total Liab	314.0M	677.2M	3.3B	4.2B	4.0B	2.1B
Deferred Long Term Liab	52.2M	43.4M	26.2M	52.0M	59.7M	41.5M
Net Invested Capital	1.6B	6.2B	9.1B	9.2B	7.7B	5.5B
Short Long Term Debt	20.2M	40.2M	1.1B	1.6B	1.4B	1.5B
Total Current Assets	794.2M	5.4B	9.3B	7.7B	5.2B	4.6B
Net Working Capital	670.0M	5.0B	6.4B	4.8B	2.6B	3.1B
Intangible Assets	57.2M	72.3M	198.3M	258.7M	205.6M	138.9M
Property Plant Equipment	574.9M	873.9M	2.2B	3.1B	3.5B	3.7B

Currently Active Assets on Macroaxis

C	Citigroup
GM	General Motors
F	Ford Motor
GM	General Motors
V	Visa Class A

Other Information on Investing in Cansino Stock

Balance Sheet is a snapshot of the financial position of Cansino Biologics at a specified time, usually calculated after every quarter, six months, or one year. Cansino Biologics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cansino Biologics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cansino currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cansino Research Development vs Ebitda Analysis

Research Development vs Ebitda

Research Development vs Ebitda Correlation Analysis

Correlation Coefficient

Research Development

Ebitda

Cansino Biologics fundamental ratios Correlations

Cansino Biologics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cansino Biologics fundamental ratios Accounts

Currently Active Assets on Macroaxis

Other Information on Investing in Cansino Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Assets
Non Currrent Assets Other	+ 1.0	Net Debt
Total Current Assets	+ 0.99	Total Assets
Short Long Term Debt	+ 0.99	Other Current Liab
Short Term Investments	+ 0.99	Total Current Liabilities
Total Liab	+ 0.99	Total Current Liabilities

Other Stockholder Equity	- 0.78	Net Debt
Other Stockholder Equity	- 0.77	Non Currrent Assets Other
Net Invested Capital	- 0.69	Other Stockholder Equity
Other Stockholder Equity	- 0.69	Net Tangible Assets
Other Stockholder Equity	- 0.69	Total Stockholder Equity
Long Term Debt	- 0.68	Retained Earnings